Indian biotechnology firm Premas Biotech’s joint venture company Oravax Medical is set to begin testing their triple antigen oral vaccine candidate against the new Omicron variant of concern.
Oramed Pharmaceuticals Inc. today announced that its majority-owned company Oravax Medical Inc.'s oral COVID-19 vaccine will be featured in the Keynote Talk at the Arena International Vaccines Virtual Conference 2021
Premas Biotech announced the development of an oral COVID-19 vaccine that has shown efficacy after a single dose, in conjunction with Oramed Pharmaceuticals.